Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3212)
All Articles published online
|
May 27, 2010 (publication date) through Nov 26, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Mancuso A. Hepatocellular carcinoma in thalassemia: A critical review. World J Hepatol 2010; 2(5): 171-174 [PMID: 21160991 DOI: 10.4254/wjh.v2.i5.171] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v2/i5/171.htm |
| Number | Citing Articles |
| 1 |
Hassan M. Moukhadder, Racha Halawi, Maria Domenica Cappellini, Ali T. Taher. Reply to Management of hepatocellular carcinoma in thalassemia and importance of the human factor. Cancer 2017; 123(6): 1073 doi: 10.1002/cncr.30550
|
| 2 |
Arthur Zimmermann. Tumors and Tumor-Like Lesions of the Hepatobiliary Tract. 2017; : 2961 doi: 10.1007/978-3-319-26956-6_165
|
| 3 |
Sandeep Soni. Gene therapies for transfusion dependent β‐thalassemia: Current status and critical criteria for success. American Journal of Hematology 2020; 95(9): 1099 doi: 10.1002/ajh.25909
|
| 4 |
Hassan M. Moukhadder, Racha Halawi, Maria Domenica Cappellini, Ali T. Taher. Hepatocellular carcinoma as an emerging morbidity in the thalassemia syndromes: A comprehensive review. Cancer 2017; 123(5): 751 doi: 10.1002/cncr.30462
|
| 5 |
A. Mancuso. Letter: hepatocellular carcinoma in thalassaemia – emerging issues and challenges for liver transplant. Alimentary Pharmacology & Therapeutics 2014; 40(11-12): 1368 doi: 10.1111/apt.12989
|
| 6 |
Said Y. Mohamed. Thalassemia Major: Transplantation or Transfusion and Chelation. Hematology/Oncology and Stem Cell Therapy 2017; 10(4): 290 doi: 10.1016/j.hemonc.2017.05.022
|
| 7 |
Irene Motta, Marta Mancarella, Alessia Marcon, Marco Vicenzi, Maria Domenica Cappellini. Management of age-associated medical complications in patients with β-thalassemia. Expert Review of Hematology 2020; 13(1): 85 doi: 10.1080/17474086.2020.1686354
|
| 8 |
Khaled M. Musallam, Irene Motta, Marta Salvatori, Mirella Fraquelli, Alessia Marcon, Ali T. Taher, Maria Domenica Cappellini. Longitudinal changes in serum ferritin levels correlate with measures of hepatic stiffness in transfusion-independent patients with β-thalassemia intermedia. Blood Cells, Molecules, and Diseases 2012; 49(3-4): 136 doi: 10.1016/j.bcmd.2012.06.001
|
| 9 |
Huang-Kai Peng, I-Ling Lin, Chien-Chih Lee, Li-Ya Wang, Cherng-Chyi Tzeng, Jan-Gowth Chang, Shyh-Chyun Yang. Synthesis and antitumor activity evaluation of anilinoquinoline derivatives by the effect on the expression of polo-like kinase. Medicinal Chemistry Research 2014; 23(3): 1437 doi: 10.1007/s00044-013-0749-3
|
| 10 |
John C. Wood. Use of Magnetic Resonance Imaging to Monitor Iron Overload. Hematology/Oncology Clinics of North America 2014; 28(4): 747 doi: 10.1016/j.hoc.2014.04.002
|
| 11 |
Andrea Mancuso, Giuseppe Butera, Margherita Rossi, Alberto Maringhini. Hepatocellular carcinoma in thalassemia and other hemoglobinopathies. Cancer 2023; 129(10): 1614 doi: 10.1002/cncr.34735
|
| 12 |
Andrea Mancuso. Management of hepatocellular carcinoma in thalassemia and importance of the human factor. Cancer 2017; 123(6): 1071 doi: 10.1002/cncr.30551
|
| 13 |
Joseph E. Maakaron, Maria Domenica Cappellini, Giovanna Graziadei, Jad Bou Ayache, Ali T. Taher. Hepatocellular carcinoma in hepatitis-negative patients with thalassemia intermedia: A closer look at the role of siderosis. Annals of Hepatology 2013; 12(1): 142 doi: 10.1016/S1665-2681(19)31397-3
|
| 14 |
Roberta D’Ambrosio, Erika Poggiali, Maria Domenica Cappellini. Treating hepatitis C in patients with hemoglobinopathies. Expert Opinion on Orphan Drugs 2015; 3(11): 1267 doi: 10.1517/21678707.2015.1086333
|
| 15 |
Current status of beta‐thalassemia and its treatment strategies. Molecular Genetics & Genomic Medicine 2021; 9(12) doi: 10.1002/mgg3.1788
|
| 16 |
Jung Wha Chung, Eun Shin, Haeryoung Kim, Ho‐Seong Han, Jai Young Cho, Young Rok Choi, Sukho Hong, Eun Sun Jang, Jin‐Wook Kim, Sook‐Hyang Jeong. Hepatic iron overload in the portal tract predicts poor survival in hepatocellular carcinoma after curative resection. Liver International 2018; 38(5): 903 doi: 10.1111/liv.13619
|
| 17 |
Rayan Bou-Fakhredin, Irene Motta, Maria Domenica Cappellini, Ali T. Taher. Clinical Complications and Their Management. Hematology/Oncology Clinics of North America 2023; 37(2): 365 doi: 10.1016/j.hoc.2022.12.007
|
| 18 |
Andrea Mancuso, Giovanni Perricone. Time to define a new strategy for management of hepatocellular carcinoma in thalassaemia?. British Journal of Haematology 2015; 168(2): 304 doi: 10.1111/bjh.13098
|
| 19 |
Paul I. Tyan, Amr H. Radwan, Assaad Eid, Anthony G. Haddad, David Wehbe, Ali T. Taher. Novel Approach to Reactive Oxygen Species in Nontransfusion-Dependent Thalassemia. BioMed Research International 2014; 2014: 1 doi: 10.1155/2014/350432
|
| 20 |
Andrea Mancuso. Management of hepatocellular carcinoma: Enlightening the gray zones. World Journal of Hepatology 2013; 5(6): 302-310 doi: 10.4254/wjh.v5.i6.302
|
| 21 |
Maher Malaeb, Ali T. Taher, Ala I. Sharara. Liver Cancer in the Middle East. 2021; : 371 doi: 10.1007/978-3-030-78737-0_23
|
| 22 |
Mohammad Hassan Hodroj, Ali Taher. Thalassemia and malignancies: Updates from the literature. Annals of the New York Academy of Sciences 2023; 1529(1): 14 doi: 10.1111/nyas.15061
|
| 23 |
Antoine Finianos, Charbel F. Matar, Ali Taher. Hepatocellular Carcinoma in β-Thalassemia Patients: Review of the Literature with Molecular Insight into Liver Carcinogenesis. International Journal of Molecular Sciences 2018; 19(12): 4070 doi: 10.3390/ijms19124070
|
| 24 |
Adriana Ceci, Laura Mangiarini, Fedele Bonifazi, Rossella Conte. Multidisciplinary Care in Haemoglobinopathies. Thalassemia Reports 2014; 4(3): 4875 doi: 10.4081/thal.2014.4875
|
| 25 |
Mohammad Hassan Hodroj, Rayan Bou-Fakhredin, Wared Nour-Eldine, Hussein A. Noureldine, Mohammad Hassan A. Noureldine, Ali T. Taher. Thalassemia and malignancy: An emerging concern?. Blood Reviews 2019; 37: 100585 doi: 10.1016/j.blre.2019.06.002
|
| 26 |
Silvia Fargion, Luca Valenti, Anna Ludovica Fracanzani. Role of iron in hepatocellular carcinoma. Clinical Liver Disease 2014; 3(5): 108 doi: 10.1002/cld.350
|
| 27 |
Ashutosh Lal, Vip Viprakasit, Elliott Vichinsky, Yongrong Lai, Meng‐Yao Lu, Antonis Kattamis. Disease burden, management strategies, and unmet needs in α‐thalassemia due to hemoglobin H disease. American Journal of Hematology 2024; 99(11): 2164 doi: 10.1002/ajh.27440
|
| 28 |
João Arezes, Niall Foy, Kirsty McHugh, Doris Quinkert, Susan Benard, Anagha Sawant, Joe N. Frost, Andrew E. Armitage, Sant-Rayn Pasricha, Pei Jin Lim, May S. Tam, Edward Lavallie, Debra D. Pittman, Orla Cunningham, Matthew Lambert, John E. Murphy, Simon J. Draper, Reema Jasuja, Hal Drakesmith. Antibodies against the erythroferrone N-terminal domain prevent hepcidin suppression and ameliorate murine thalassemia. Blood 2020; 135(8): 547 doi: 10.1182/blood.2019003140
|
| 29 |
Samah F. Abozeid, Rasha A. Elkholy, Tamer A. Elbedewy, Mahmoud F. Seliem. Soluble fms-like tyrosine kinase-1 as a predictive marker for iron overload in adult patients with transfusion-dependent beta-thalassemia major. Tanta Medical Journal 2024; 52(3): 258 doi: 10.4103/tmj.tmj_50_23
|
| 30 |
Andrea Mancuso. Evidence-based medicine and Management of Hepatocellular Carcinoma in Thalassemia. BMC Gastroenterology 2020; 20(1) doi: 10.1186/s12876-020-01542-2
|
| 31 |
Racha Halawi, Irene Motta, Ali Taher, Maria Domenica Cappellini. Deferasirox: an orphan drug for chronic iron overload in non-transfusion dependent thalassemia syndromes. Expert Opinion on Orphan Drugs 2016; 4(6): 677 doi: 10.1080/21678707.2016.1182018
|
| 32 |
Arthur Zimmermann. Tumors and Tumor-Like Lesions of the Hepatobiliary Tract. 2016; : 1 doi: 10.1007/978-3-319-26587-2_165-1
|
| 33 |
Khaled M. Musallam, Maria D. Cappellini, John C. Wood, Ali T. Taher. Iron overload in non-transfusion-dependent thalassemia: a clinical perspective. Blood Reviews 2012; 26: S16 doi: 10.1016/S0268-960X(12)70006-1
|
| 34 |
Hassan M. Moukhadder, Joseph E. Roumi, Rayan Bou-Fakhredin, Ali T. Taher. Hepatocellular Carcinoma in a β-Thalassemia Intermedia Patient: Yet Another Case in the Expanding Epidemic. Hemoglobin 2018; 42(1): 58 doi: 10.1080/03630269.2018.1434197
|
| 35 |
Paschalis Paschos, Efthimia Vlachaki, Chrisoula Pasvanti, Emmanouil Sinakos, Anastasia Kalpaka, Philippos Klonizakis, Vasilios Perifanis. Safety and Efficacy of Combination Therapy with Pegylated Interferon Alpha-2a and Ribavirin in Treating Patients with Chronic Hepatitis C and Beta-Thalassaemia Major: A Greek Single-Center Experience. Acta Haematologica 2011; 126(4): 231 doi: 10.1159/000330516
|
| 36 |
Christine C. Hsu, Nizar H. Senussi, Kleber Y. Fertrin, Kris V. Kowdley. Iron overload disorders. Hepatology Communications 2022; 6(8): 1842 doi: 10.1002/hep4.2012
|
| 37 |
Pierre Brissot, Olivier Loreal. Management of Liver Complications in Haemoglobinopathies. Thalassemia Reports 2014; 4(3): 4869 doi: 10.4081/thal.2014.4869
|